With Prolonged Effect
Phase II of clinical trials of a Russian antiviral drug “Ridostin Pro” performed at the First Infectious Hospital by the State Scientific Center of Virology and Biotecnologies Vector, is completed. Now the application will be submitted for marketing authorization.
Ridostin-pro is an immunomodulator, an antiviral drug with prolonged effect. The drug will be effective for prevention and treatment of acute respiratory disorders and influenza.